

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211745 A1

(51) International Patent Classification:

A61K 9/22 (2006.01) A61P 29/00 (2006.01)
A61K 31/451 (2006.01) A61P 31/14 (2006.01)
A61P 7/00 (2006.01)

(21) International Application Number:

PCT/US2021/027335

(22) International Filing Date:

14 April 2021 (14.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/010,009 14 April 2020 (14.04.2020) US

(71) Applicant: **EXCALIBUR PHARMACEUTICALS, INC.** [US/US]; 9 Sniffen Court, New York, NY 10016 (US).

(72) Inventors: **AGUILAR-CORDOVA, Estuardo**; c/o Cell Therapy And Technology, SA De CV, Calzada de las Bombas No. 128, Bodega 1, Col. Ex Hacienda Coapa, Delegacion Coyoacan, Mexico City, 04980 (MX). **AGUILAR, Laura**; c/o Cell Therapy And Technology, SA De CV, Calzada de las Bombas No. 128, Bodega 1, Col. Ex Hacienda Coapa, Delegacion Coyoacan, Mexico City, 04980


(MX). **MAGAÑA CASTRO, José Agustín, Rogelio**; c/o Cell Therapy And Technology, SA De CV, Calzada de las Bombas No. 128, Bodega 1, Col. Ex Hacienda Coapa, Delegacion Coyoacan, Mexico City, 04980 (MX).

(74) Agent: **CHAO, Jessica, J.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PIRFENIDONE FOR CORONAVIRUS TREATMENT



Evaluable patients: patients that receive at least 3 days of drug

(57) Abstract: Provided herein are methods and uses involving pirfenidone pharmaceutical compositions (e.g., extended-release pirfenidone pills (e.g., tablets)) in treating COVID-19, treating and/or preventing viremia and/or viremia-induced disease caused by a virus, and/or an infection with a virus (e.g., DNA virus, RNA virus, for example, coronavirus (e.g., severe acute respiratory syndrome coronaviruses-2 (SARS-CoV-2) and variants thereof, severe acute respiratory syndrome-associated coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV)), in a subject (e.g., subject with COVID-19). Provided are methods of reducing elevated levels of one or more markers of inflammation (e.g., CRP, ferritin, LDH), inhibiting an inflammatory response (e.g., virus-induced) and/or inhibiting a cascade by one or more pro-inflammatory cytokines (e.g., TNF- α , IEN- γ , IL-1 β , IL-6, IL-12) and/or in a subject (e.g., a subject with COVID-19 optionally having liver contraindications for pirfenidone).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*